Saxenda for weight loss: what the evidence actually says

What did @drashleypower actually say?

Dr. Power, a Royal College Certified General Internist, gave a concise overview of Saxenda (liraglutide) as a Health Canada-approved weight management medication. She described its mechanism as "slowing down gastric emptying, increasing feelings of fullness, and reducing appetite," listed common GI side effects, and flagged serious risks including pancreatitis, gallbladder issues, kidney problems, and thyroid tumors. She closed by recommending viewers consult their healthcare provider.

The video is largely informational and avoids making dramatic cure claims or dosing recommendations. That's worth noting in a TikTok landscape full of people doing the opposite. Throughout, she mispronounces both "Saxenda" and "liraglutide" consistently, which is a minor credibility ding but doesn't change the medical content.

Does the science back this up?

Yes, mostly. The mechanism description is accurate but incomplete. Liraglutide does slow gastric emptying and increase satiety, but it also acts centrally on hypothalamic appetite centers, a point the SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, NEJM) specifically examined. The drug's central nervous system effects are arguably as important as the gut effects.

The side effect profile she describes matches what the clinical literature shows. The SCALE trial reported nausea in roughly 40% of participants and serious GI events in a meaningful subset. The thyroid tumor concern comes from rodent studies showing C-cell tumors with liraglutide exposure, which carried over to a black box warning from both Health Canada and the FDA. Human epidemiological data on thyroid cancer risk remains inconclusive (Bezin et al., 2023, Diabetes Care), but the warning is real and she was right to mention it. The pancreatitis and gallbladder signals are also well-documented in GLP-1 receptor agonist post-marketing data.

What did they get wrong (or right)?

The mechanism description is accurate but missing a key piece. Liraglutide works on GLP-1 receptors in the brain, not just the gut. Framing it purely as a gastric and appetite drug undersells what makes GLP-1 agonists genuinely interesting pharmacologically. That said, for a short-form video, what she included is not wrong.

She got the approval framing right. Saxenda is approved in Canada for adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity. The phrase "obese or overweight with a weight-related complication" is an accurate plain-language summary of those criteria.

One gap worth flagging: she didn't mention that Saxenda requires daily subcutaneous injections with a dose titration schedule, which significantly affects tolerability and adherence. The SCALE trial's dropout rate due to adverse events was non-trivial. For viewers considering this medication, that context matters. She also didn't mention that liraglutide is the same molecule used in Victoza for type 2 diabetes, at a lower dose. That's a relevant piece of context she skipped.

What should you actually know?

Saxenda produces meaningful but modest weight loss compared to newer GLP-1 options. The SCALE trial showed an average of about 8% body weight reduction at one year with liraglutide 3 mg, compared to roughly 15% with semaglutide 2.4 mg in the STEP 1 trial (Wilding et al., 2021, NEJM). Both are approved; both work. But if you're choosing between them in 2024, that efficacy gap is a real clinical consideration your doctor should walk you through.

The thyroid tumor warning is a black box, not a footnote. People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not use Saxenda. Dr. Power mentioned thyroid nodules and tumors but didn't convey the contraindication clearly enough for a general audience.

Finally, weight regain after stopping liraglutide is well-documented. A follow-up analysis from the SCALE trial showed most participants regained lost weight within a year of discontinuation. This is not a short-term fix, and the chronic disease framing of obesity treatment matters here.